Hepatitis C Virus Resistance-Associated Substitutions in Mexico
Viruses · 2025
DOI: 10.3390/v17020169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Alexis Jose-Abrego und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, Fray Antonio Alcalde, Guadalajara 44280, Mexico. Hauptthemen laut MEDLINE: Hepacivirus, Drug Resistance, Viral, Antiviral Agents, Hepatitis C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Humanidades, Ciencias y Tecnologías, Consejo Nacional de Ciencia, Humanidades y Tecnología (CONAHCYT), Programa de Fortalecimiento de Institutos, Centros y Laboratorios de Investigación 2021, Universidad de Guadalajara.
Abstract (Originalsprache)
Hepatitis C virus (HCV) is susceptible to resistance-associated substitutions (RASs) in the NS3, NS5A, and NS5B nonstructural genes, key targets of the direct-acting antivirals (DAAs). This study aimed to assess the prevalence and distribution of RASs across different HCV subtypes in Mexico. A Genbank dataset of 566 HCV sequences was analyzed. Most sequences were from Mexico City (49.1%, 278/566) and Jalisco (39.4%, 223/566). The NS5B region was the most sequenced (59.7%, 338/566). The most frequent HCV subtypes were 1a (44.0%, 249/566), 1b (28.6%, 162/566), 2b (9.5%, 54/566), and 3a (6.2%, 35/566). Subtypes 1a (57.4%, 128/223) and 3a (12.6%, 28/223) were significantly higher in Jalisco than in Mexico City (34.2%, 95/278 and 2.5%, 7/278), whereas subtype 1b was higher in Mexico City (34.5%, 96/278 vs. 14.8%, 33/223). Subtype 1a increased from 2019 to 2024, representing 49.4% (123/249) of all reported cases. RASs were detected in NS3 (6.7%, 1/15), NS5A (2.9%, 3/102), and NS5B (0.3%, 1/349), with the most frequent mutations being Q80K, Y93H, and S282T, respectively, and detected in subtypes 1b (n = 3), 1a (n = 1), and 2a (n = 1). In conclusion, Mexico’s HCV sequencing-based surveillance is limited. Subtype 1a predominated, but frequencies varied across states. The prevalence of RASs varied by gene from 0.3% to 6.7%. Establishing regional sequencing centers for NS3, NS5A, and NS5B is crucial to monitoring Mexico’s DAA-resistant mutations and HCV subtype genetic diversity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, Fray Antonio Alcalde, Guadalajara 44280, Mexico.
- Health Sciences Center, University of Guadalajara, Guadalajara 44340, Mexico.
- Doctoral Program Molecular Biology in Medicine, Health Sciences Center, University of Guadalajara, Guadalajara 44340, Mexico.
ORCID-Profile: Saul Laguna-Meraz, Sonia Roman, Irene M Mariscal-Martinez
Förderung
- Consejo Nacional de Humanidades, Ciencias y Tecnologías
- Consejo Nacional de Ciencia, Humanidades y Tecnología (CONAHCYT)
- Programa de Fortalecimiento de Institutos, Centros y Laboratorios de Investigación 2021, Universidad de Guadalajara
Zitieren
APA
Jose-Abrego, A., Laguna-Meraz, S., Roman, S., Mariscal-Martinez, I. M., & Panduro, A. (2025). Hepatitis C Virus Resistance-Associated Substitutions in Mexico. Viruses. https://doi.org/10.3390/v17020169
Vancouver
Jose-Abrego A, Laguna-Meraz S, Roman S, Mariscal-Martinez IM, Panduro A. Hepatitis C Virus Resistance-Associated Substitutions in Mexico. Viruses. 2025. doi:10.3390/v17020169
BibTeX
@article{JoseAbrego2025,
author = {Jose-Abrego, Alexis and Laguna-Meraz, Saul and Roman, Sonia and Mariscal-Martinez, Irene M and Panduro, Arturo},
title = {Hepatitis C Virus Resistance-Associated Substitutions in Mexico},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17020169}
}
EUVIMED